{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:20:18Z","timestamp":1790738418887,"version":"4.1.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Despite the dramatic improvements in outcomes for the majority of chronic myeloid leukemia (CML) patients over the past 2 decades, a similar improvement has not been observed in the more advanced stages of the disease. Blast phase CML (BP-CML), although infrequent, remains poorly understood and inadequately treated. Consequently, the key initial goal of therapy in a newly diagnosed patient with chronic phase CML continues to be prevention of disease progression. Advances in genomic investigation in CML, specifically related to BP-CML, clearly demonstrate we have only scratched the surface in our understanding of the disease biology, a prerequisite to devising more targeted and effective therapeutic approaches to prevention and treatment. Importantly, the introduction of the concept of \u201cCML-like\u201d acute lymphoblastic leukemia (ALL) has the potential to simplify the differentiation between BCR::ABL1-positive ALL from de novo lymphoid BP-CML, optimizing monitoring and therapeutics. The development of novel treatment strategies such as the MATCHPOINT approach for BP-CML, utilizing combination chemotherapy with fludarabine, cytarabine, and idarubicin in addition to dose-modified ponatinib, may also be an important step in improving treatment outcomes. However, identifying patients who are high risk of transformation remains a challenge, and the recent 2022 updates to the international guidelines may add further confusion to this area. Further work is required to clarify the identification and treatment strategy for the patients who require a more aggressive approach than standard chronic phase CML management.<\/jats:p>","DOI":"10.1182\/hematology.2023000446","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:11:48Z","timestamp":1702048308000},"page":"459-468","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":6,"title":["Accelerated-phase CML: de novo and transformed"],"prefix":"10.1182","volume":"2023","author":[{"given":"Naranie","family":"Shanmuganathan","sequence":"first","affiliation":[{"name":"1 Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia"},{"name":"2 Department of Haematoloxgy, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia"},{"name":"3 Adelaide Medical School, University of Adelaide, Adelaide, Australia"},{"name":"4 Department of Genetics and Molecular Pathology & Centre for Cancer Biology, SA Pathology, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[{"name":"1 Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, Australia"},{"name":"2 Department of Haematoloxgy, Royal Adelaide Hospital and SA Pathology, Adelaide, Australia"},{"name":"3 Adelaide Medical School, University of Adelaide, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"12","key":"2023120815071226500_hem2023000446C1","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600\u200a\u2009mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2023120815071226500_hem2023000446C2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2023120815071226500_hem2023000446C3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023120815071226500_hem2023000446C4","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2023120815071226500_hem2023000446C5","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2023120815071226500_hem2023000446C6","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"2023120815071226500_hem2023000446C7","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1038\/s41375-020-0826-9","article-title":"High-risk additional chromosomal abnormalities at low blast counts herald death by CML","volume":"34","author":"Hehlmann","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"2023120815071226500_hem2023000446C8","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv"},{"issue":"22","key":"2023120815071226500_hem2023000446C9","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2023120815071226500_hem2023000446C10","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2015-05-646489","article-title":"Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2023120815071226500_hem2023000446C11","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2023120815071226500_hem2023000446C12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cyto.b.21250","article-title":"Detection of small abnormal B- lymphoblast populations at diagnosis of chronic myelogenous leukemia, BCR-ABL1+: incidence, phenotypic features, and clinical implications","volume":"92","author":"Vrotsos","year":"2017","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"2023120815071226500_hem2023000446C13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12308-022-00487-7","article-title":"Incidence and immunophenotype of abnormal lymphoblast populations at diagnosis of chronic myeloid leukaemia in chronic phase","volume":"15","author":"Barge","year":"2022","journal-title":"J Hematop"},{"issue":"5","key":"2023120815071226500_hem2023000446C14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/cyto.b.21357","article-title":"Small, abnormal B lymphoid blast populations in chronic myelogenous leukemia at diagnosis: does this finding indicate an accelerated course?","volume":"90","author":"Soma","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"2023120815071226500_hem2023000446C15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cyto.b.21958","article-title":"Sudden blast phase in pediatric chronic myeloid leukemia-chronic phase with abnormal lymphoid blasts detected by flow cytometry at diagnosis: can it be considered a warning sign?","volume":"100","author":"Vijayasekharan","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"2023120815071226500_hem2023000446C16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/cncr.29142","article-title":"Predicting early blast transformation in chronic-phase chronic myeloid leukemia: is immunophenotyping the missing link?","volume":"121","author":"El Rassi","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"2023120815071226500_hem2023000446C17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"8","key":"2023120815071226500_hem2023000446C18","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1080\/10428194.2021.1894647","article-title":"Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice","volume":"62","author":"Ravi","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2023120815071226500_hem2023000446C19","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"issue":"21","key":"2023120815071226500_hem2023000446C20","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/bloodadvances.2018024844","article-title":"Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia","volume":"2","author":"Chhabra","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2023120815071226500_hem2023000446C21","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"issue":"20","key":"2023120815071226500_hem2023000446C22","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"issue":"12","key":"2023120815071226500_hem2023000446C23","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2023120815071226500_hem2023000446C24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"issue":"8","key":"2023120815071226500_hem2023000446C25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2019002969","article-title":"Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study","volume":"135","author":"Soverini","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023120815071226500_hem2023000446C26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2023120815071226500_hem2023000446C27","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2020004834","article-title":"An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia","volume":"135","author":"Ko","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2023120815071226500_hem2023000446C28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Adnan Awad","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023120815071226500_hem2023000446C29","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2023120815071226500_hem2023000446C30","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2023120815071226500_hem2023000446C31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jmoldx.2022.04.004","article-title":"RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia","volume":"24","author":"Shanmuganathan","year":"2022","journal-title":"J Mol Diagn"},{"issue":"9","key":"2023120815071226500_hem2023000446C32","first-page":"2380","article-title":"Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention","volume":"108","author":"Shanmuganathan","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023120815071226500_hem2023000446C33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood-2022-158743","article-title":"Additional mutational events at diagnosis of CML confer inferior failure-free survival and molecular response for patients treated with frontline imatinib but not for patients treated with frontline second-generation tyrosine kinase inhibitors","volume":"140","author":"Shanmuganathan","year":"2022","journal-title":"Blood"},{"issue":"3","key":"2023120815071226500_hem2023000446C34","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2014.116954","article-title":"Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"100","author":"Brissot","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"2023120815071226500_hem2023000446C35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbmt.2019.10.017","article-title":"Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study","volume":"26","author":"DeFilipp","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023120815071226500_hem2023000446C36","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of chronic myeloid leukemia in advanced phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front Oncol"},{"issue":"4","key":"2023120815071226500_hem2023000446C37","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023120815071226500_hem2023000446C38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-021-01106-1","article-title":"Impact of frontline treatment approach on outcomes of myeloid blast phase CML","volume":"14","author":"Saxena","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2023120815071226500_hem2023000446C39","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2352-3026(21)00370-7","article-title":"Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase \u00bd trial","volume":"9","author":"Copland","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2023120815071226500_hem2023000446C40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12874-017-0381-x","article-title":"Implementing the EffTox dose-finding design in the Matchpoint trial","volume":"17","author":"Brock","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"2023120815071226500_hem2023000446C41","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/ajh.25939","article-title":"Phase I\/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia","volume":"95","author":"Abaza","year":"2020","journal-title":"Am J Hematol"},{"issue":"10","key":"2023120815071226500_hem2023000446C42","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2023120815071226500_hem2023000446C43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12185-014-1566-2","article-title":"Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study","volume":"99","author":"Baccarani","year":"2014","journal-title":"Int J Hematol"},{"issue":"5","key":"2023120815071226500_hem2023000446C44","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2023120815071226500_hem2023000446C45","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2023120815071226500_hem2023000446C46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"issue":"20","key":"2023120815071226500_hem2023000446C47","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Na\u00efve Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2023120815071226500_hem2023000446C48","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","article-title":"Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"issue":"6","key":"2023120815071226500_hem2023000446C49","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/459\/2175710\/459shanmuganathan.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/459\/2175710\/459shanmuganathan.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:12:03Z","timestamp":1702048323000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/459\/506411\/Accelerated-phase-CML-de-novo-and-transformed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000446","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}